Home > Insider Trading > Filing (0000950170-24-088538)

Filing Details

Accession Number:: 0000950170-24-088538
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-07-31 16:05:09
Reporting Period:: 2024-07-29

Accepted Time:: 2024-07-31 16:05:09
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1607678	Viking Therapeutics Inc.	VKTX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1264949	Greg Zante	C/O Viking Therapeutics, Inc. 9920 Pacific Heights Blvd, Suite 350 San Diego CA 92121	Chief Financial Officer	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock, Par Value $0.00001 Per Share	Acquisiton	2024-07-29	6,667	$0.00	181,521	No	4	A	Direct
Common Stock, Par Value $0.00001 Per Share	Acquisiton	2024-07-29	21,667	$0.00	203,188	No	4	A	Direct
Common Stock, Par Value $0.00001 Per Share	Disposition	2024-07-30	12,662	$56.96	190,526	No	4	S	Direct
Common Stock, Par Value $0.00001 Per Share	Disposition	2024-07-30	2,974	$57.71	187,552	No	4	S	Direct
Common Stock, Par Value $0.00001 Per Share	Disposition	2024-07-30	500	$58.71	187,052	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The reported securities were subject to a performance restricted stock unit award that was granted on January 4, 2021, 33.33% of which vested on July 29, 2024 upon the achievement of a non-financial performance goal.
The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2024, 33.33% of which vested on July 29, 2024 upon the achievement of a non-financial performance goal.
These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock unit awards.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.46 to $57.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.46 to $58.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.54 to $58.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.